Sloan Foundation Supports Hastings Center Work on Ethical Issues in Synthetic Biology
News Dec 22, 2008
Synthetic biology takes genetic engineering techniques developed in the 1970s many steps forward. Those methods were largely confined to moving genes from one organism to another.
Now, using techniques from molecular biology, computer science, and engineering, synthetic biology aims to create wholly new genetic recipes that the older engineering simply could not cook up. More effective medicines, intelligent tumor-seeking bacteria, and cheap biofuels are just a few of the hoped-for applications-while new weapons of terror are one of the fears.
The Hastings Center, long at the forefront of interdisciplinary research into ethical issues in emerging technology, has received a $500,000 grant from the Alfred P. Sloan Foundation for a two-year project to examine these issues.
The project is being led by Thomas H. Murray, PhD, president of the center; Gregory E. Kaebnick, PhD, research scholar and editorial director; Erik Parens, PhD, senior research scholar; and Mary Crowley, director of public affairs and communication.
Roger Brent, PhD, president and research director of The Molecular Sciences Institute at the University of California, San Francisco, will serve as science advisor. It builds on earlier work at the Center that was funded by a planning grant from the Sloan Foundation, which highlighted two areas requiring deeper investigation: the nonphysical moral concerns synthetic biology raises, and what role those concerns should play in public policy.
“We have come up against similar problems in other domains-most notably, in work on nanotechnology and gene transfer technology-but synthetic biology poses them especially sharply and pressingly,” said Dr. Murray.
The new project includes three meetings with presentations by an interdisciplinary working group including scientists, philosophers, social scientists, public policy experts, and theologians. It is designed to make serious contributions to the scholarly and scientific literature on synthetic biology, as well as engage science journalists on the issue.
The Center’s work will contribute to an initiative by the Sloan Foundation that supports a comprehensive look at synthetic biology. The other participants in the initiative are the J. Craig Venter Institute, which will explore a range of societal concerns surrounding synthetic biology; and the Woodrow Wilson International Center for Scholars, which will work with the scientific community and stakeholders in government, nongovernmental organizations, and the larger public to ensure that the public and policymakers are informed, and that risks are minimized.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.